Quidelortho Corp (OQ:QDEL)

Business Focus: Medical Diagnostic & Testing Equipment

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 9975 Summers Ridge Road
SAN DIEGO CA 92121
Tel: N/A
Website: https://www.quidelortho.com
IR: See website
<
Key People
Brian J. Blaser
President, Chief Executive Officer
Robert J. Bujarski
Interim President, Chief Operating Officer, Executive Vice President
Michael S. Iskra
Interim Chief Executive Officer, Executive Vice President, Chief Commercial Officer
Joseph M. Busky
Chief Financial Officer
Michelle A. Hodges
Senior Vice President, General Counsel, Corporate Secretary
Werner E. Kroll
Senior Vice President - Research and Development
Louise M. Brandy
Chief Information Officer
   
Business Overview
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
Financial Overview
For the fiscal year ended 31 December 2023, Quidelortho Corp revenues decreased 8% to $3B. Net loss totaled $10.1M vs. income of $548.7M. Revenues reflect North America segment decrease of 26% to $1.88B. Net loss reflects Selling, General & Administrative Expens increase of 23% to $601.4M (expense), Term Loan increase from $74.5M to $178.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $9.66 to -$0.15.
Employees: 7,100 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $5,090M as of Dec 31, 2023
Annual revenue (TTM): $2,998M as of Dec 31, 2023
EBITDA (TTM): $709.70M as of Dec 31, 2023
Net annual income (TTM): -$10.10M as of Dec 31, 2023
Free cash flow (TTM): $70.90M as of Dec 31, 2023
Net Debt Last Fiscal Year: $2,247M as of Dec 31, 2023
Shares outstanding: 66,878,683 as of Mar 18, 2024
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.